PolyPid partners with Azurity to commercialize D-PLEX100 in US, Canada
Share
Listen to the news
PolyPid partners with Azurity to commercialize D-PLEX100 in US, Canada
  • PolyPid entered an exclusive deal with Azurity to commercialize D-PLEX100 in the US, Canada for surgical site infection prevention.
  • Upfront payment set at USD 15 million on signing; USD 15 million milestone due on FDA NDA acceptance expected in August 2026.
  • Eligible for about USD 300 million in additional regulatory, development, sales milestones; tiered royalties in the mid-teens to mid-twenties.
  • PolyPid to manufacture and supply D-PLEX100; Azurity to fund clinical development, including potential US, Canada label expansion beyond abdominal surgery.
  • US launch targeted for Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210730PRIMZONEFULLFEED9764424) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending